Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.

Nature communications

Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial.

Annals of internal medicine

To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications.

Current atherosclerosis reports

Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis.

Journal of clinical gastroenterology

Heart failure in 2025: new insights, therapies, and clinical directions.

Journal of thoracic disease

Tirzepatide attenuates doxorubicin-induced cardiotoxicity via mitochondrial function improvement.

Translational cancer research

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Journal of diabetes and metabolic disorders

Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.

Endocrinology, diabetes & metabolism

Everyone says peptides cause cancer. I pulled the studies. Here's what they actually show. 06:25 BPC-157 08:40 DSIP 09:54 Epitalon 12:15 GHK-Cu 14:45 KPV 16:03 LL-37 18:41 MOTS-c 20:00 Retatrutide 21:19 Semaglutide 22:24 SS-31 24:13 Thymosin Alpha-1 25:47 Tirzepatide https://t.co/2RBkMubEQP

YOUR STOMACH makes a peptide that REGROWS torn tendons — in 14 days. In 2024, the FDA blocked pharmacies from compounding it. It’s called BPC-157. Body Protection Compound. Studied in 190+ published papers since 1993: • accelerated tendon-to-bone healing that failed on its https://t.co/OXn2s02GV7

What 2026 research-chem buyers actually order — top 10 by share of all in-scope COAs in our corpus over the last 60 days: Retatrutide — 10.4% Tirzepatide — 8.5% BPC-157 — 7.8% GHK-Cu — 4.8% Tesamorelin — 4.4% MOTS-C — 4.1% Ipamorelin — 3.8% NAD+ — 3.2% Semaglutide — 3.1% TB-500

🧬 The potential of peptide therapy is growing, but patients must prioritize safety! Many clinics are offering these treatments without solid FDA backing. Always consult a physician first. #Peptides #Longevity @ez_peptides

Why Retatrutide is Better Than Other GLP-1s: 1. Triple Action Power • Retatrutide activates GLP-1, GIP, and glucagon receptors — most others only target GLP-1 (like Semaglutide) or GLP-1 + GIP (like Tirzepatide). https://t.co/d5qjmF2BX1 https://t.co/wOBoPEcVsW

Unlock serious weight loss with GLP-1 peptides! 🔥 Patients are seeing 15-30% body weight reduction, reduced cravings, and better metabolic health. Premium GLP-1s (Semaglutide & Tirzepatide) are available for research.

@LisaD138845 @elonmusk @tunguz **GLPs (GLP-1 receptor agonists) like Ozempic/Wegovy (semaglutide) and Zepbound/Mounjaro (tirzepatide) are synthetic peptide drugs.** **Active ingredient:** - Ozempic/Wegovy: semaglutide (lab-made GLP-1 analog) - Zepbound/Mounjaro: tirzepatide (dual GLP-1/GIP agonist)

retatrutide Phase 3 data just dropped. 28.3% average weight loss at 80 weeks (12mg dose). for context: tirzepatide peaked at 22.5% in SURMOUNT-1. semaglutide hit 16.9% in STEP 1. triple agonist (GLP-1 + GIP + glucagon) vs dual for tirzepatide, single for semaglutide.